Plain-English translation of NCT06967753 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether dolutegravir plus lamivudine—a two-drug combination taken as one pill once a day—works well and is safe for transgender women living with HIV whose virus is already well-controlled. Right now, most people take three or more drugs; this trial explores whether fewer drugs might work just as well while being simpler to take.
Simpler treatment regimens can make it easier for people to take their medications every day and stick with their treatment plan long-term. This study wants to know if this two-drug combination can work as well as the three-drug regimens transgender women are currently using.
You likely qualify if…
You likely don't qualify if…
You will have a screening visit (up to 30 days) to confirm you qualify. Then you'll switch to taking the two-drug combination as a single daily pill for 48 weeks, with regular follow-up visits to check how you're doing. After the 48 weeks, there's a final 4-week follow-up visit to make sure everything is going well. You'll have blood tests to confirm your virus stays undetectable and to monitor for any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Argentina
Phase
Post-approval monitoring
Sponsor
UBATEC
Collaborators
ViiV Healthcare, Hospital Fernandez
Enrollment target
~50 participants
Started
July 2025
Primary completion
December 2026
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Martín Jaume, MD
Hospital Fernández, Infectious Diseases Division
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.